Skip to main content

Travoprost ophthalmic Disease Interactions

There are 3 disease interactions with travoprost ophthalmic.

Moderate

Ophthalmic PG analogues (applies to travoprost ophthalmic) macular edema

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Aphakia, Pseudophakia, Retinal Disorder

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic prostaglandin analogues. Most cases occurred in patients with aphakia, pseudophakia with a torn posterior lens capsule, or known risk factors for macular edema (e.g., posterior uveitis, certain retinal disorders). Therapy with ophthalmic prostaglandin analogues should be administered cautiously in these patients.

References

  1. "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn PROD (2001):
  2. "Product Information. Lumigan (bimatoprost ophthalmic)." Allergan Inc PROD (2001):
  3. "Product Information. Travatan (travoprost ophthalmic)." Alcon Laboratories Inc PROD (2001):
  4. "Product Information. Latisse (bimatoprost topical ophthalmic)." Allergan Inc (2009):
View all 4 references
Moderate

Ophthalmic PG analogues (applies to travoprost ophthalmic) uveitis

Moderate Potential Hazard, Moderate plausibility.

Bimatoprost, latanoprost, and travoprost are synthetic prostaglandin analogues. Theoretically, these agents may mimic endogenous prostaglandins and mediate ocular inflammatory responses. In clinical trials, uveitis and iritis have been reported rarely. Therapy with ophthalmic prostaglandin analogues should be administered cautiously in patients with active intraocular inflammation.

References

  1. "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn PROD (2001):
  2. "Product Information. Lumigan (bimatoprost ophthalmic)." Allergan Inc PROD (2001):
  3. "Product Information. Travatan (travoprost ophthalmic)." Alcon Laboratories Inc PROD (2001):
Moderate

Ophthalmic PGF2a analogues- renal/liver disease

Moderate Potential Hazard, Low plausibility. Applicable conditions: Renal Dysfunction

Prostaglandin F2-alpha analogues are hydrolyzed by esterases in the cornea to their corresponding active free acid form, which is absorbed systemically and metabolized by the liver via fatty acid beta-oxidation, then eliminated by the kidney. These agents have not been adequately studied in the treatment of patients with impaired renal and/or hepatic function. Therapy with ophthalmic prostaglandin F2-alpha analogues should be administered cautiously in such patients.

References

  1. "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn PROD (2001):
  2. "Product Information. Travatan (travoprost ophthalmic)." Alcon Laboratories Inc PROD (2001):

Travoprost ophthalmic drug interactions

There are 7 drug interactions with travoprost ophthalmic.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer